Alyeska Investment Group
RNTX

Alyeska Investment Group’s Rein Therapeutics RNTX Stock Holding History

Alyeska Investment Group’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-540,000
Closed -$1.91M – 688
2024
Q3 		$1.91M Hold
540,000
– – 0.01% 422
2024
Q2 		$1.5M Buy
+540,000
New +$2.22M 0.01% 437

Other funds holding RNTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Alyeska Investment Group's RNTX Position: Q4 2024 in Review

Alyeska Investment Group sold out of Rein Therapeutics (RNTX) in Q4 2024, closing a stake of 540,000 shares — an estimated $1.91M sold.

Alyeska Investment Group first reported a position in RNTX in Q2 2024 and held it in 2 quarters. The position peaked at $1.91M in Q3 2024. 31 funds tracked by Wall St. Rank hold RNTX as of Q4 2024.

  • Alyeska Investment Group reported no remaining Rein Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Alyeska Investment Group sold 540,000 Rein Therapeutics shares in Q4 2024, an estimated $1.91M.
  • Alyeska Investment Group first reported a position in Rein Therapeutics in Q2 2024 and held it in 2 quarters.
  • Alyeska Investment Group's Rein Therapeutics position peaked at $1.91M in Q3 2024.
  • 31 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2024.

Based on Alyeska Investment Group's 13F filing for Q4 2024, filed 14 Feb 2025.